[Why and how evaluating driving abilities in patients with neurodegenerative diseases?]

Pourquoi et comment évaluer l’aptitude à la conduite automobile chez les patients souffrant de maladies neurodégénératives ?

Journal

Geriatrie et psychologie neuropsychiatrie du vieillissement
ISSN: 2115-7863
Titre abrégé: Geriatr Psychol Neuropsychiatr Vieil
Pays: France
ID NLM: 101553404

Informations de publication

Date de publication:
01 Jun 2021
Historique:
pubmed: 27 5 2021
medline: 26 10 2021
entrez: 26 5 2021
Statut: ppublish

Résumé

Many studies have shown that individuals with neurodegenerative diseases are a risk factor for being involved in a traffic accident. However, driving is critical for social integration and independence in daily life. Lack of consensus and standardized assessment of driving abilities in these patients is problematic. This article summarizes the various multidisciplinary evaluations proposed, their limits, and the societal issues raised by such an evaluation. Several neuropsychological theoretical models have attempted to describe the cognitive processes involved in car driving. Moreover, several studies have sought to determine which cognitive functions are impaired in distinct disorders and best explained driving errors. We here describe the relationships between neuropsychological performance and driving abilities for the most frequent neurodegenerative disorders. It appears that a full neuropsychological assessment is necessary to determine accurately which patients are at risk of dangerous driving. In particular, cognitive impairments in attention, visual-spatial abilities, executive functions, and/or information processing speed appear to be the most likely involved in driving errors.

Identifiants

pubmed: 34037523
pii: pnv.2021.0933
doi: 10.1684/pnv.2021.0933
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

191-201

Auteurs

Chloé Lazeras (C)

Centre mémoire de ressources et de recherches, Pôle de neurosciences cliniques, CHU de Bordeaux, France.

Mégane Cartier (M)

Centre mémoire de ressources et de recherches, Pôle de neurosciences cliniques, CHU de Bordeaux, France.

Marie Bonnet (M)

Centre mémoire de ressources et de recherches, Pôle de neurosciences cliniques, CHU de Bordeaux, France, Centre expert Parkinson, Pôle de neurosciences cliniques, CHU de Bordeaux, France.

Brice Laurens (B)

Centre mémoire de ressources et de recherches, Pôle de neurosciences cliniques, CHU de Bordeaux, France, Centre expert Parkinson, Pôle de neurosciences cliniques, CHU de Bordeaux, France.

Wassilios G Meissner (WG)

Centre expert Parkinson, Pôle de neurosciences cliniques, CHU de Bordeaux, France, Université de Bordeaux, CNRS, UMR 5293, Institut des maladies neurodégénératives, France.

Vincent Planche (V)

Centre mémoire de ressources et de recherches, Pôle de neurosciences cliniques, CHU de Bordeaux, France, Université de Bordeaux, CNRS, UMR 5293, Institut des maladies neurodégénératives, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH